<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">2589393</PMID>
        <DateCompleted>
            <Year>1990</Year>
            <Month>01</Month>
            <Day>02</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2017</Year>
            <Month>09</Month>
            <Day>08</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0002-9343</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>87</Volume>
                    <Issue>5A</Issue>
                    <PubDate>
                        <Year>1989</Year>
                        <Month>Nov</Month>
                        <Day>30</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The American journal of medicine</Title>
                <ISOAbbreviation>Am. J. Med.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Ciprofloxacin-caffeine: a drug interaction established using in vivo and in vitro investigations.</ArticleTitle>
            <Pagination>
                <MedlinePgn>89S-91S</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>The inhibitory effects of ciprofloxacin and other quinolone derivatives on the hepatic cytochrome P450-dependent metabolism of caffeine have been investigated in humans. In vivo studies involved an intraindividual comparison of the single-dose kinetics of caffeine before and during quinolone administration in 12 healthy men. Changes of enzymatic caffeine degradation by the quinolones were studied in vitro using human liver microsomes from three donors. Enoxacin and pipemidic acid markedly prolonged caffeine elimination in vivo. A positive correlation exists between the doses of enoxacin or ciprofloxacin and the prolongation (increases) in the caffeine elimination half-life. Decreases in caffeine elimination, using doses of ciprofloxacin in the upper part of the recommended dose range, were approximately 1.5-fold in comparison with untreated control subjects, whereas in the case of enoxacin there was a sixfold change. In vitro results with enoxacin, ofloxacin, ciprofloxacin, and pipemidic acid show a competitive inhibition (Dixon plots) of caffeine 3-demethylation. Ciprofloxacin and enoxacin showed the strongest inhibitory effects in vitro, whereas ofloxacin had the lowest inhibitory effect. These results are qualitatively reflected in the in vivo results; however, the clinical effects may be dependent on pharmacokinetic disposition of the quinolone and this could explain the weak inhibitory action of ciprofloxacin in vivo.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Harder</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Clinical Pharmacology, University Hospital, Frankfurt, Federal Republic of Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fuhr</LastName>
                    <ForeName>U</ForeName>
                    <Initials>U</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Staib</LastName>
                    <ForeName>A H</ForeName>
                    <Initials>AH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wolff</LastName>
                    <ForeName>T</ForeName>
                    <Initials>T</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Am J Med</MedlineTA>
            <NlmUniqueID>0267200</NlmUniqueID>
            <ISSNLinking>0002-9343</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>325OGW249P</RegistryNumber>
                <NameOfSubstance UI="D015365">Enoxacin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>3G6A5W338E</RegistryNumber>
                <NameOfSubstance UI="D002110">Caffeine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>5E8K9I0O4U</RegistryNumber>
                <NameOfSubstance UI="D002939">Ciprofloxacin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002110" MajorTopicYN="N">Caffeine</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002939" MajorTopicYN="N">Ciprofloxacin</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003640" MajorTopicYN="N">Dealkylation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015365" MajorTopicYN="N">Enoxacin</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1989</Year>
                <Month>11</Month>
                <Day>30</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1989</Year>
                <Month>11</Month>
                <Day>30</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1989</Year>
                <Month>11</Month>
                <Day>30</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">2589393</ArticleId>
            <ArticleId IdType="pii">0002-9343(89)90031-4</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>